Tag: patients

NANJING, China, June 5, 2026 /PRNewswire/ -- NTRK gene fusions have been identified as oncogenic drivers in adult and pediatric patients with pan-solid tumors....

SARASOTA, Fla., June 5, 2026 /PRNewswire/ -- Pines of Sarasota Healthcare, LLC experienced a data security incident that involved personal and / or protected...

DALLAS, June 05, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on June 1, 2026, the Compensation Committee of Taysha's Board of Directors granted four new employees, in the aggregate, restricted stock units (RSUs) representing 714,700 shares of the Company’s common stock and an option to purchase 468,600 shares of the Company's common stock in connection with their employment. The RSUs and stock option were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).

Patients Can Now Connect with Licensed Clinicians through the Informed Pain Care Platform to Receive Timely Evaluation and Access to Non-Opioid Treatment Options for...

Subordinate Voting Shares expected to begin trading under ticker "TRLV" on Wednesday, June 10TALLAHASSEE, Fla., June 5, 2026 /PRNewswire/ -- Trulieve Cannabis Corp. (CSE: TRUL)...

Breaking Through the "Blind Selection" Dilemma in Clinical Practice — TFC Taipei Fertility Center Introduces AI Scoring System to Help Infertile Couples End the...

BOSTON, June 5, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient...

Including United's offer for Spirit customers, eBay's response to GameStop's acquisition proposal, and a new partnership between major telecom providers.Plus, a recap of May's...

Fangzhou showcased its “AI + Chronic Disease Services” digital solution developed in collaboration with Tencent Health.

European Commission approval expands the indication of lomitapide in the European Union (EU) to include children 5 years of age and older with HoFH, an ultra-rare genetic disorder affecting LDL-cholesterol levels

European Commission approval expands the indication of lomitapide in the European Union (EU) to include children 5 years of age and older with HoFH, an ultra-rare genetic disorder affecting LDL-cholesterol levels

The study showed that orelabrutinib was safe and well tolerated in participants with SLE.

SHANGHAI, June 4, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that its independently developed innovative...

SINGAPORE, June 4, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has completed the...